LENZ Therapeutics, Inc. (LENZ)

17.54 -0.15 (-0.85%) At close: 04:00PM EDT

LENZ Therapeutics, Inc.

445 Marine View Avenue
Suite 320
Del Mar, CA 92014
United States
(858) 925-7000
https://www.lenz-tx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Evert B. Schimmelpennink	President, CEO, Secretary & Director	886.54k	N/A	1972
Mr. Shawn Olsson	Chief Commercial Officer	532.13k	N/A	1983
Mr. Marc G. Odrich M.D.	Chief Medical Officer	576.95k	N/A	1959
Mr. James W. McCollum	Co-Founder & Director	N/A	N/A	1955
Mr. Gerald Horn	Senior Scientific Advisor & Founder	N/A	N/A	N/A
Mr. Daniel R. Chevallard CPA	Chief Financial Officer	N/A	N/A	1980
Mr. Domenick Porfidia	Vice President of Sales	N/A	N/A	N/A
Mr. David Murphy	Senior Director of Marketing & Alliance Development	N/A	N/A	N/A
Mr. Marvin J. Garrett	Senior Vice President of Regulatory & Quality	N/A	N/A	1951

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Corporate governance

LENZ Therapeutics, Inc.’s ISS governance QualityScore as of 1 July 2024 is 8. The pillar scores are Audit: 9; Board: 5; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.